Hongbo Lu, Ph.D. has served as a member of our board of directors since April 2020. Dr. Lu is the founding member of NEXTBio Capital, a newly launched biotechnology investment firm. Dr. Lu has over 20 years of healthcare investment management experience in both public securities and private companies, including prior roles previously served as Managing Partner of Vivo Capital, a healthcare investment firm, from December 2020 to January 2024, Managing Partner at Lilly Asia Ventures, a venture capital firm, from January 2017 to December 2020, and Managing Director at OrbiMed Advisors. Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics, Inc., Crown Bioscience Inc., Createrna Science and Technology Co., Ltd., Avedro, Inc., Rgenta Therapeutics Inc., Ronovo Surgical, Inc., Avistone Biotechnology Co., Inc., and BlossomHill Therapeutics, Inc. Dr. Lu currently serves on the board of directors for RiboX Therapeutics Ltd., Visirna Therapeutics (Suzhou) Co., Ltd. and Zenas BioPharma, Inc. Dr. Lu received her undergraduate degree in Material Science and Engineering from Tsinghua University, China, her Ph.D. in Biological Engineering from the University of Washington and her M.B.A. from the University of California, Berkeley. We believe Dr. Lu is qualified to serve on our board of directors due to her experience as a director of public and private companies in the biopharmaceutical industry and experience in venture capital and the life science industry.